GYRE logo

GYRE THERAPEUTICS INC

GYRENASDAQ
πŸ† #2820 by market capEarnings Mar 10 Β· PostUS Equity
β€”β€”
Quote unavailable
πŸ””
Track GYRE
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$461M
Small Cap
πŸ“ˆRevenue Growth (YoY)
10.2%
Healthy
πŸ“ŠGross Margin
94.2%
High
πŸ’΅FCF Margin
-21.1%
Thin
βš–οΈP/S Ratio
3.8x
Fair
Otter Score
80
Strong
No chart data available for GYRE.

Trading Snapshot

Day Range
β€”
52-Week Range
$3.97 – $9.14
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
109.5M
Next Earnings
2027-03-10

Fundamentals Snapshot

Annual Revenue
$117M
Last Q Revenue
$33M
P/E Ratio
-15.1
P/S Ratio
3.8x
EPS (TTM)
$-0.24
Dividend Yield
0.00%
Dilution (1yr)
+0.6%
GYRE logo

GYRE THERAPEUTICS INC

GYRE
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$117Mβ–² +10.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
95.4%β–Ό βˆ’1.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$11Mβ–Ό βˆ’29.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$180Kβ–Ό βˆ’97.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
102.9Mβ–² +0.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$36Mβ–² +$26M YoY
StockOtter Β· stockotter.space

About GYRE THERAPEUTICS INC

Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
80/100
Analyst data unavailable.

Latest News & Updates

News unavailable.